Testing of our SERION ELISA agile SARS-CoV-2 IgG
Outstanding study results
In a comparative study from Strömer et al. 2020 the performance of eight different Anti-SARS-CoV-2 IgG immunoassays was analyzed using 26 convalescent sera from PCR-confirmed cases, 27 sera containing neutralizing antibodies against SARS-CoV-2 and 100 pre-pandemic sera from 2018/2019.
- “Both tests [Virion and Abbott] turned out to be the most sensitive and specific assays in the validation part of the study.”
- “While the N-based IgG assay [Abbott] revealed the existence of two groups of individuals, and one of them showed a rapid decrease of IgG indices within a few months, the IgG reactivity in the S protein-based assay [Virion] was found to be more stable.”
- “This is in-line with a previous preprint (Ripperger et al.) and could suggest that the latter test [Virion] is better suited for epidemiological studies, especially when it comes to questions of prevalence.”
 SARS-CoV-2 RNA was previously detected in the PCR test.  SARS-CoV-2-neutralizing antibodies with a titer >1:10 were demonstrated in the plaque reduction neutralization test (PRNT).  100 stored sera from 2018/2019
Note: The highest values are shown in green, the lowest values are marked in red.
Click here to go to the study!
If you have any questions regarding our SARS-CoV-2 Immunoassays or antigens, please feel free to contact our product management: